Hengrui Medicine (600276.SH) drugs included in the list of proposed breakthrough therapy varieties.

Wisdom Finance News APP report that Hengrui Medicine (600276.SH) has announced that its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd. injectable rituximab biosimilar (SHR-A1811) and adalimumab biosimilar injection have been included in the list of breakthrough therapies under review by the National Medical Products Administration Drug Evaluation Center ("Drug Evaluation Center"). The public notice period is 7 days, and this is the 9th time that rituximab biosimilar has been included in the list of breakthrough therapies.